Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2008-07-01
2008-07-01
Shiao, Rei-tsang (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S020000, C536S021000, C536S022100, C536S029100
Reexamination Certificate
active
07393938
ABSTRACT:
This invention provides compounds represented by the structure of the general formula (A):wherein L is a lipid or a phospholipid, Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol, Y is either nothing or a spacer group ranging in length from 2 to 30 atoms, X is a physiologically acceptable monomer, dimer, oligomer, or polymer, wherein X is a glycosaminoglycan; and n is a number from 1 to 1000, wherein any bond between L, Z, Y and X is either an amide or an esteric bond.
REFERENCES:
patent: 4604375 (1986-08-01), Teng
patent: 4624919 (1986-11-01), Kokusho
patent: 4654327 (1987-03-01), Teng
patent: 5064817 (1991-11-01), Yedgar et al.
patent: 5169636 (1992-12-01), Nanba et al.
patent: 5354853 (1994-10-01), Staveski
patent: 5401511 (1995-03-01), Margalit
patent: 5464942 (1995-11-01), Sakurai et al.
patent: 5470578 (1995-11-01), Aoki et al.
patent: 5512671 (1996-04-01), Piantadose
patent: 5733892 (1998-03-01), Sakurai et al.
patent: 6022866 (2000-02-01), Falk et al.
patent: 6043231 (2000-03-01), Pruzanski et al.
patent: 6071532 (2000-06-01), Chaikof et al.
patent: 6162787 (2000-12-01), Sorgente et al.
patent: 6171614 (2001-01-01), Chaikof et al.
patent: 6180596 (2001-01-01), Tsao
patent: 6325385 (2001-12-01), Iwashita
patent: 6749813 (2004-06-01), David
patent: 0581282 (1994-02-01), None
patent: 04082893 (1992-03-01), None
patent: 09030970 (1997-02-01), None
patent: 09030979 (1997-02-01), None
patent: WO 87/02777 (1987-05-01), None
patent: WO 9628544 (1996-09-01), None
patent: WO 9701330 (1997-01-01), None
patent: WO 98016198 (1998-04-01), None
Albini, A, Iwamoto, Y, Kleinman. HK, Martin, GR, Aaronson, SA, Kozlowski, JM and McEwan, RN (1987) “A rapid in vitro assay for quantitating the invasive potential of tumor cells”Cancer Res47(12):3239-45.
Balsinde. J. Balboa, MA, Yedgar, S and Dennis, EA (2000) “Group V phospholipase A(2)-mediated oleic acid mobilization in lipopolysaccharide-stimulated P388D(1) macrophages”J Biol Chem275(7):4783-6.
Beck, G, Yard. BA. Schulte. J. Oberacker, R, Van Ackern, K. Van Der Woude, F.J, Krimsky, M. Kaszkin, M and Yedgar, S (2002) “Inhibition of LPS-induced chemokine production in human lung endothelial cells by lipid conjugates anchored to the membrane”Br J Pharmacol135(7):1665-74.
Cabanas, C and Hogg, N (1993) “Ligand intercellular adhesion molecule 1 has a necessary role in activation of integrin lymphocyte function-associated molecule 1”Proc Natl Acad Sci U S A90(12):5838-42.
Chen, WM, Soria, J, Soria. C. Krimsky, M and Yedgar, S (2002) “Control of capillary formation by membrane-anchored extracellular inhibitor of phospholipase A(2)”FEBS Lett522(1-3):113-8.
Dan. P, Dagan, A, Krimsky, M, Pruzanski, W, Vadas, P and Yedgar, S (1998) “Inhibition of type I and type II phospholipase A2 by phosphatidyl-ethanolamine linked to polymeric carriers”Biochemistry37(17):6199-204.
Darville. T. Yedgar. S. Krimsky. M. Andrews. CW. JR . Jungas. T and Ojcius, DM (2004) “Protection againstChlamydia trachomatisinfection in vitro and modulation of inflammatory response in vivo by membrane-bound glycosaminoglycans”Microbes Infect6(4):369-76.
Krimsky. M, Dagan, A, Aptekar, L. Ligumsky, M and Yedgar, S (2000) “Assessment of intestinal permeability in rats by permeation of inulin-fluorescein”J Basic Clin Physiol Pharmacol11(2):143-53.
Krimsky. M, Yedgar, S, Aptekar, L, Schwob, O, Goshen, G, Gruzman, A. Sasson, S and Ligumsky, M (2003) “Amelioration of TNBS-induced colon inflammation in rats by phospholipase A2 inhibitor”Am J Physiol Gastrointest Liver Physiol285(3):G586-92.
Margolis-Nunno, H, Ben-Hur, E, Gottlieb, P, Robinson. R. Oetjen, J and Horowitz, B (1996) “Inactivation by phthalocyanine photosensitization of multiple forms of human immunodeficiency virus in red cell concentrates”Transfusion36(8):743-50.
Murthy, SN, Cooper. HS. Shim. H. Shah, RS, Ibrahim, SA and Sedergran, DJ (1993) “Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin”Dig Dis Sci38(9):1722-34.
Okayasu. I, Hatakeyama, S, Yamada, M, Ohkusa, T, Inagaki, Y and Nakaya, R (1990) “A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice”Gastroenterology98(3):694-702.
Schmiel, DH and Miller, VL (1999) “Bacterial phospholipases and pathogenesis”Microbes Infect1(13):1103-12.
Schnitzer, E, Dagan, A, Krimsky, M, Lichtenberg, D, Pinchuk, I. Shinar, H and Yedgar, S (2000) “Interaction of hyaluronic acid-linked phosphatidylethanolamine (HyPE) with LDL and its effect on the susceptibility of LDL lipids to oxidation”Chem Phys Lipids104(2):149-60.
Schnitzer, E, Pinchuk, I, Fainaru, M, Lichtenberg, D and Yedgar, S (1998) “LDL-associated phospholipase A does not protect LDL against lipid peroxidation in vitro”Free Radic Biol Med24(7-8):1294-303.
Yard, BA, Yedgar, S, Scheele, M, Van Der Woude, D, Beck, G, Heidrich. B. Krimsky, M, Van Der Woude, FJ and Post. S (2002) “Modulation of IFN-gamma-induced immunogenicity by phosphatidylethanolamine-linked hyaluronic acid”Transplantation73(6):984-92.
Yedgar, S, Lichtenberg. D and Schnitzer, E (2000) “Inhibition of phospholipase A(2) as a therapeutic target”Biochim Biophys Acta1488(1-2):182-7.
Schnitzer, E , et al (1999) “The Interaction of hyaluronic-phosphatidylethanolamine with low density lipoprotein (LDL) and it's effect on copper induced LDL oxidation” (Biophysical Journal vol. 76, No. 1 Part 2).
Prostaglandins, leukotrienes, phospholipase, platelet activating factor, and cytokines: an integrated approach to inflammation of human skin Greaves MW. Camp RD. Arch Dermatol Res 1988;280 Suppl:S33-41. Institute of Dermatology, St. Thomas's Hospital, London, UK.
Greaves MW and Camp RD (1988) “Prostaglandins, leukotrienes, phospholipase, platelet activating factor, and cytokines: an integrated approach to inflammation of human skin.”Arch Dermatol Res280:S33-41.
Krimsky, M, Dagan, A, Aptekar, L, Ligumsky, M and Yedgar, S (2000) “Assessment of intestinal permeability in rats by permeation of inulin-fluorescein”J Basic Clin Physiol Pharmacol11(2):143-53.
Krimsky, M, Yedgar, S, Aptekar, L, Schwob, O, Goshen, G, Gruzman, A, Sasson S and Ligumsky, M (2003) “Amelioration of TNBS-induced colon inflammation in rats by phospholipase A2 inhibitor”Am J Physiol Gastrointest Liver Physiol285(3):G586-92.
Margolis-Nunno, H, Ben-Hur, E, Gottlieb, P, Robinson, R, Oetjen, J and Horowitz, B (1996) “Inactivation by phthalocyanine photosensitization of multiple forms of human immunodeficiency virus in red cell concentrates”Transfusion36(8):743-50.
Murthy, SN, Cooper, HS, Shim, H, Shah, RS, Ibrahim, SA and Sedergran, DJ (1993) “Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin”Dig Dis Sci38(9):1722-34.
Okayasu, I, Hatakeyama, S, Yamada, M, Ohkusa, T, Inagaki, Y and Nakaya, R (1990) “A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice”Gastroenterology98(3):694-702.
Schmiel, DH and Miller, VL (1999) “Bacterial phospholipases and pathogenesis”Microbes Infect1(13):1103-12.
Schnitzer, E, Dagan, A, Krimsky, M, Lichtenberg, D, Pinchuk, I, Shinar, H and Yedgar, S (2000) “Interaction of hyaluronic acid-linked phosphatidylethanolamine (HyPE) with LDL and its effect on the susceptibility of LDL lipids to oxidation”Chem Phys Lipids104(2):149-60.
Schnitzer, E, Yedgar, S, Danino, D, Talmon, Y and Lichtenberg, D, (1999) “The Interaction of hyaluronic-phosphatidylethanolamine with low density lipoprotein (LDL) and its effect on copper induced LDL oxidation”Biophysical Journal76(1): Part 2.
Schnitzer, E, Pinchuk, I, Fainaru, M, Lichtenberg, D and Yedgar, S (1998) “LDL-associated phospholipase A does not protect LDL against lipid peroxidation in vitro”
Pearl Cohen Zedek Latzer LLP
Shiao Rei-tsang
Teitelbaum Rachel
Yissum Research Development Company of the Hebrew University of
LandOfFree
Use of lipid conjugates in the treatment of diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of lipid conjugates in the treatment of diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of lipid conjugates in the treatment of diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2747789